Loading
A phase 1/2 trial of Zilovertamab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) is a phase 1/2 interventional study registered as NCT05562830 by Merck Sharp & Dohme LLC, with 48 participants planned, started 2022-11-16 and due to reach its primary completion in 2029-02-26. Interventions recorded: Zilovertamab vedotin, Pembrolizumab and MK-3120.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.